All In MedTech

FDA Clearance Tracker · P040001

X STOP INTERSPINOUS PROCESS DECOMPRESSION SYSTEM

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Nov 21, 2005 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product code

Decided

Nov 21, 2005

Approval withdrawn

Time to decision

685 days

Received Jan 6, 2004. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P040001
Device name
X STOP INTERSPINOUS PROCESS DECOMPRESSION SYSTEM
Applicant location
Memphis, TN
Received
Jan 6, 2004
Decided
Nov 21, 2005
Decision
Approval withdrawn
Expedited review
Yes, flagged as expedited in FDA's record.
Supplements
19 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code NQO

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE X STOP INTERSPINOUS PROCESS DECOMPRESSION SYSTEM. THE DEVICE IS INDICATED FOR TREATMENT OF PATIENTS AGED 50 OR OLDER SUFFERING FROM NEUROGENIC INTERMITTENT CLAUDICATION SECONDARY TO A CONFIRMED DIAGNOSIS OF LUMBAR SPINAL STENOSIS (WITH X-RAY, MRI, AND /OR CT EVIDENCE OF THICKENED LIGAMENTUM FLAVUM, NARROWED LATERAL RECESS AND/OR CENTRAL CANAL NARROWING). THE X STOP IS INDICATED FOR THOSE PATIENTS WITH MODERATELY IMPAIRED PHYSICAL FUNCTION WHO EXPERIENCE RELIEF IN FLEXION FROM THEIR SYMPTOMS OF LEG/BUTTOCK/GROIN PAIN, WITH OR WITHOUT BACK PAIN, AND HAVE UNDERGONE A REGIMEN OF AT LEAST 6 MONTHS OF NONOPERATIVE TREATMENT. THE X STOP MAY BE IMPLANTED AT ONE OR TWO LUMBAR LEVELS IN PATIENTS IN WHOM OPERATIVE TREATMENT IS INDICATED AT NO MORE THAN TWO LEVELS.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code NQO (Prosthesis, spinous process spacer/plate).
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Medtronic Sofamor Danek, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.